Hepatobiliary Problems After Kidney Transplantation
Özet
Hepatobiliary complications are frequently encountered in kidney transplant recipients and represent an underappreciated cause of morbidity in this population. The post-transplant milieu — characterized by chronic immunosuppression, polypharmacy, and metabolic derangement — creates a unique substrate for hepatic injury that differs substantially from that seen in the general population. This chapter provides a comprehensive review of the principal categories of hepatobiliary disease following kidney transplantation, including drug-induced liver injury (DILI) attributable to immunosuppressants, antifungals, antibiotics, and statins; viral hepatitis reactivation and de novo infection with hepatitis B (HBV) and hepatitis C (HCV) viruses; biliary tract disease including cholelithiasis, cholangitis, and choledocholithiasis; and metabolic-associated fatty liver disease (MAFLD/NAFLD) driven by post-transplant metabolic syndrome. Diagnostic evaluation is structured around liver function test (LFT) pattern analysis — hepatocellular, cholestatic, or mixed — supplemented by viral serology, abdominal imaging, and liver biopsy where indicated. A stepwise algorithmic approach and multidisciplinary management framework are presented. Figures illustrating the diagnostic algorithm and pathophysiological mechanisms are provided to facilitate clinical application. With up to 50% of kidney transplant recipients experiencing clinically relevant LFT abnormalities at some point post-transplant, systematic surveillance and early intervention are paramount to preserving both hepatic and allograft function.
Referanslar
Pottanat N, Friederich A, LaMotte J. End-stage kidney disease, dialysis, and transplant basics. In: Psychosocial Considerations in Pediatric Kidney Conditions: Guidance for Collaborative Practice. Springer; 2024. p. 67–94.
Gabrielli F, Bernasconi E, Toscano A, Avossa A, Cavicchioli A, Andreone P, et al. Side effects of immunosuppressant drugs after liver transplant. Pharmaceuticals. 2025;18(3):342.
El Sibai R, Freedman SR, Gatz JD. A narrative review of the evaluation and management of liver transplant complications in the emergency department. The Journal of Emergency Medicine. 2023;64(5):596–609.
Moura AF, Moura-Neto JA, Ribeiro BdM, Oliveira PR, Freitas AGd, Costa AL, et al. Post-liver transplant kidney dysfunction: incidence of acute kidney injury and chronic kidney disease and risk factors related to chronic kidney disease development. Diseases. 2025;13(5):144.
Jothimani D, Marannan NK, Rela M. Acute liver failure and liver transplantation. Indian Journal of Gastroenterology. 2025;44(3):298–310.
Sharma P, Izzy M, Ghabril MS, Serper M, Clark VC, Ison MG, et al. AASLD AST practice guideline on adult liver transplantation: diagnosis and post-transplant management of non-graft-related complications. Liver Transplantation. 2025;31
Mistry A, Bhattacharya A, Mondal M, Bhattacharjee S, Bhattacharya A, Ghosh SB, et al. Calcineurin inhibitors: current role, toxicity management, and future frontiers in immunosuppression. Molecular Neurobiology. 2026;63(1):275
Vij M. Pathology of liver transplantation. In: Fundamentals of Transplant Hepatology. Springer; 2026. p. 637–677.
Irving PM, Gecse KB. Optimizing therapies using therapeutic drug monitoring: current strategies and future perspectives. Gastroenterology. 2022;162(5):1512–1524.
Lou Y, Wang Y, Liu J, Wang YJ, Wang J, Ma S, et al. Voriconazole-induced liver injury: incidence patterns and risk factors in a retrospective cohort. Antimicrobial Agents and Chemotherapy. 2025;69(9):e00487-25.
Lamprecht DG Jr, Saseen JJ, Shaw PB. Clinical conundrums involving statin drug-drug interactions. Progress in Cardiovascular Diseases. 2022; 75:83–89.
Teschke R, Danan G. Advances in idiosyncratic drug-induced liver injury issues: new clinical and mechanistic analysis due to RUCAM use. International Journal of Molecular Sciences. 2023;24(13):10855.
Maertens J, Pagano L, Azoulay E, Warris A. Liposomal amphotericin B—the present. Journal of Antimicrobial Chemotherapy. 2022;77(Suppl 2):11–20.
Vutien P, Nguyen MH. HBV reactivation in immunosuppressed patients: screening, prevention, and management including solid organ transplant recipients. Viruses. 2025;17(3):388.
Chang Y, Jeong SW, Jang JY. Hepatitis B virus reactivation associated with therapeutic interventions. Frontiers in Medicine. 2022; 8:770124.
Mak LY, Hu TH, Yap DY. Renal safety profiles of tenofovir alafenamide, tenofovir disoproxil fumarate, and entecavir for chronic hepatitis B. Alimentary Pharmacology & Therapeutics. 2026;63(7):945–954.
Rinaldi L, Giorgione C, Mormone A, Esposito F, Rinaldi M, Berretta M, et al. Non-invasive measurement of hepatic fibrosis by transient elastography: a narrative review. Viruses. 2023;15(8):1730.
Zheng L, Ye ZY, Ma JJ. Effect of cholesterol metabolism on hepatolithiasis. World Journal of Gastroenterology. 2025;31(1):99960.
Chauhan K, Khan A, Chowdhury S, Ross HM, Parra NS, Halegoua-DeMarzio D. Risk of metabolic syndrome and cardiovascular disease after liver transplantation. Livers. 2022;2(2):85–96.
Colaci C, Gambardella ML, Scarlata GGM, Boccuto L, Colica C, Luzza F, et al. Dysmetabolic comorbidities and NAFLD: a stairway to MASLD. Hepatoma Research. 2024;10.
Biciusca T, Stan SI, Balteanu MA, Cioboata R, Ghenea AE, Danoiu S, et al. Role of the fatty liver index in NAFLD management: a systematic review. Diagnostics. 2023;13(21):3316.
Alluhayyan OB, Almutawa FM, Alghamdi YI, Alyousef KA, Altaleb KA, AlGhamdi HA, et al. Use of semaglutide in diabetes care post renal transplantation. Current Transplantation Reports. 2025;12(1):9.
Tincopa MA, Loomba R. Non-invasive diagnosis and monitoring of NAFLD and NASH. The Lancet Gastroenterology & Hepatology. 2023;8(7):660–670.
Gadour E. Lessons from 60 years of liver transplantation: advancements, challenges, and future directions. World Journal of Transplantation. 2025;15(1):93253.
Al-Worafi YM. Liver diseases. In: Handbook of Complementary, Alternative, and Integrative Medicine. CRC Press; 2025. p. 367–388.
